or
Remember me
Back
Winnipeg – TheNewswire - August 15 2024 - Cytophage Technologies Ltd. (TSXV:CYTO) (“Cytophage” or the “Company”), the only publicly traded phage company that is focused on bacteriophage solutions for both animal health and human health, is pleased to announce the launch of a simplified application option for bacteriophages that can treat multiple types of bacteria, such as E. coli and Salmonella, throughout the lifecycle of a chicken. The lyophilized tablets were first developed and tested in the spring of 2024 and are now being targeted for wider application.
The lyophilized phage tablets are designed to provide an alternative to the liquid form commonly used in phage therapy. This lyophilized (freeze-dried/stabilized) product represents a technological breakthrough, offering increased flexibility, stability, and application versatility. This innovative development is in direct response to Cytophage working with the poultry industry on phage products with the goal to reduce the use of broad-spectrum antibiotics and replace them with targeted phages.
Product Highlights:
Ready-to-use, dissolves easily in water to simplify the process for the farmer.
Dose controlled, can simply be added to the specified water levels (see Image 1).
Temperature stable, does not require a cold chain making it easily usable in hotter climates such as South-East Asia.
Lightweight packaging, easily portable to the barn.
Cytophage CEO, Dr. Steven Theriault, commented: ”The importance of eliminating the need for a cold chain cannot be overstated. Offering phages in lyophilized form represents a competitive advantage over other phage producers who have only liquid products that require refrigeration. Our innovative manufacturing increases our products’ heat tolerance and shelf-life.”
Image 1: Lyophilized phage tablets easily dissolve in the specified water levels
Cytophage anticipates leveraging this innovation globally across all existing and pending product lines. The Company believes it is currently the only phage company worldwide capable of delivering a lyophilized phage product at scale, without significantly increasing costs for consumers.
For further information please contact:
Heather Medwick
Chief Operating Officer
heather@cytophage.com
431 388 8873
Cytophage Investor Alerts: https://cytophage.com/subscribe/
About Cytophage Technologies
Cytophage Technologies (TSXV:CYTO) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Committed to addressing the global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.
Receive investor kits and email updates from Stockhouse and directly from these companies.
